找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Immunotherapy Meets Oncology; In Honor of Christop Cedrik Michael Britten,Sebastian Kreiter,Hans-Geor Book 2014 Springer Internation

[复制链接]
查看: 31887|回复: 57
发表于 2025-3-21 19:41:57 | 显示全部楼层 |阅读模式
书目名称Cancer Immunotherapy Meets Oncology
副标题In Honor of Christop
编辑Cedrik Michael Britten,Sebastian Kreiter,Hans-Geor
视频video
概述Provides a comprehensive update on the state of the art in cancer immunology.Describes the most promising therapeutic concepts, with coverage of combination therapies and personalized medicine.Discuss
图书封面Titlebook: Cancer Immunotherapy Meets Oncology; In Honor of Christop Cedrik Michael Britten,Sebastian Kreiter,Hans-Geor Book 2014 Springer Internation
描述.This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing..Cancer Immunotherapy Meets Oncology. is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients..
出版日期Book 2014
关键词Biomarkers; Cancer Immunotherapy; Immuno-Oncology; Novel Treatments
版次1
doihttps://doi.org/10.1007/978-3-319-05104-8
isbn_softcover978-3-319-38126-8
isbn_ebook978-3-319-05104-8
copyrightSpringer International Publishing Switzerland 2014
The information of publication is updating

书目名称Cancer Immunotherapy Meets Oncology影响因子(影响力)




书目名称Cancer Immunotherapy Meets Oncology影响因子(影响力)学科排名




书目名称Cancer Immunotherapy Meets Oncology网络公开度




书目名称Cancer Immunotherapy Meets Oncology网络公开度学科排名




书目名称Cancer Immunotherapy Meets Oncology被引频次




书目名称Cancer Immunotherapy Meets Oncology被引频次学科排名




书目名称Cancer Immunotherapy Meets Oncology年度引用




书目名称Cancer Immunotherapy Meets Oncology年度引用学科排名




书目名称Cancer Immunotherapy Meets Oncology读者反馈




书目名称Cancer Immunotherapy Meets Oncology读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-22 00:18:44 | 显示全部楼层
发表于 2025-3-22 03:18:22 | 显示全部楼层
发表于 2025-3-22 07:21:42 | 显示全部楼层
发表于 2025-3-22 11:16:08 | 显示全部楼层
发表于 2025-3-22 15:25:28 | 显示全部楼层
Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Ca safety profile on the other. Here, we briefly summarize the regulatory classification of immunotherapy approaches. The second part focuses on the evolving regulatory landscape for nonpersonalized and personalized cancer vaccines that have been in the focus of the CIMT regulatory research group during the last years.
发表于 2025-3-22 17:13:20 | 显示全部楼层
发表于 2025-3-22 21:35:17 | 显示全部楼层
The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic) conditions, engineered by viral vector- or nucleic acid-based gene transfer with the CAR, amplified to therapeutic numbers, and readministered to the patient. Successes in recent trials sustain the hope that specifically redirected patient T cells can control cancer in the long term.
发表于 2025-3-23 03:37:23 | 显示全部楼层
Book 2014er Immunotherapy Meets Oncology. is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients..
发表于 2025-3-23 06:16:42 | 显示全部楼层
Book 2014nto an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identificat
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-28 15:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表